Cullinan Therapeutics, Inc. 8-K

What Happened
Cullinan Therapeutics, Inc. (CGEM) filed an 8-K reporting the results of its Annual Meeting of Stockholders held June 16, 2026. Stockholders elected two Class III directors—Nadim Ahmed and Stephen Webster—for three‑year terms, ratified KPMG LLP as the independent registered public accounting firm for fiscal 2026, and approved the advisory (non‑binding) vote on executive compensation.

Key Details

• Directors elected (Class III, three‑year terms):
  • Nadim Ahmed: 37,519,241 votes for; 12,116,759 withheld; 4,126,430 broker non‑votes.
  • Stephen Webster: 36,963,086 votes for; 12,672,914 withheld; 4,126,430 broker non‑votes.
• Auditor ratified: KPMG LLP approved by vote of 53,722,477 for, 36,815 against, 3,138 abstentions (0 broker non‑votes).
• Advisory vote on executive compensation: 48,536,734 for, 1,092,209 against, 7,057 abstentions; 4,126,430 broker non‑votes.
• Form 8‑K signed by CFO Mary Kay Fenton on June 16, 2026.

Why It Matters
These outcomes confirm board composition and corporate governance continuity (two directors re/elected) and secure KPMG as the company’s auditor for 2026, which affects financial reporting oversight. The strong advisory vote on executive compensation signals shareholder support for management pay policies (though the vote is non‑binding). Broker non‑votes on director and pay matters indicate a portion of shares did not vote on those items, which can affect vote margins.